Directorate Change

Belluscura PLC

03 October 2023

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Belluscura plc

("Belluscura" or the "Company" or "Group")

Directorate Change

Belluscura Announces New CFO

Belluscura has appointed Simon Neicheril as Chief Financial Officer

LONDON, U.K. and PLANO, TX, U.S. (3 October 2023). Belluscura plc (AIM:BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that Tony Dyer, Chief Financial Officer, is stepping down from this role and the Board with immediate effect. Simon Neicheril has joined the Company as its new Chief Financial Officer (CFO), a Board position, with immediate effect. Tony will remain with the Company to ensure both a smooth handover to Simon and to continue to support the business in the UK on a part-time basis.

With a large proportion of the Company's operations located in the US, and immediate growth plans in Asia, Tony and the Board have agreed that it is in the best interests of the Company to align its financial base alongside its operations in the US and Simon will be located at the Company's headquarters in Texas.

Simon joins from Pace Industries LLC, a $600m revenue manufacturing company with nine locations across the US and Mexico, where he held an interim CFO role. He previously held the role of CFO at GlobalStep, a high growth global software testing company with operations in Canada, the United Kingdom, Romania, and India.

He brings over 20 years of experience having served in a range of senior finance and CFO roles within a variety of industries and worked as a consultant for Big 4 firms. In addition, his broader experience includes having built and scaled finance functions for high-growth and international companies, and led IPO preparedness, investor relations, and ERP selection and implementation.

Simon graduated from Marquette University, USA, with a Bachelor of Science in Accounting. He later went on to receive a Master of Business Administration from the Cox School of Business at Southern Methodist University, USA. He is a Certified Public Accountant.

Adam Reynolds, Chairman of the Board, Belluscura plc, commented:

"We are pleased to have Simon join the Company as we expand operations in the US and globally. We greatly appreciate the hard work and dedication of Tony and are pleased he is staying with the Company on a part-time basis."

Bob Rauker, Chief Executive Officer, Belluscura plc, commented:

 "The addition of Simon will be welcome in the US where we continue to scale for the launch of DISCOV-R and expanded global distribution of the X-PLOR. Tony has been integral to the launch and early growth of Belluscura and I am delighted he is remaining with the company."

AIM Rules Schedule 2(g) disclosures

Pursuant to Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies, Simon Joseph Neicheril, aged 64, is, or has during the last five years, been a director or partner of the following companies and partnerships:

Current Directorships or Partnerships	Previous Directorships or Partnerships
-	GlobalStep Ltd
	GlobalStep LLC Pace Industries Inc

For further information please contact:

Belluscura plc	Tel: [phone]
Adam Reynolds, Chairman Robert Rauker, Chief Executive Officer Anthony Dyer, Company Secretary
SPARK Advisory Partners Limited Nominated Adviser	Tel: [phone]
Neil Baldwin / Jade Bayat
Dowgate Capital Limited Broker	Tel: [phone]
James Serjeant / Russell Cook
MHP Financial PR & Investor Relations	Tel: [phone] email: [e-mail]
Katie Hunt/Matthew Taylor

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

 

END